ABT
Abbott LaboratoriesPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted EPS non-GAAP | $1.15 | Q1 2026 | — |
| Comparable sales growth non-GAAP | 3.7% | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABT
this stock
Abbott Laboratories
|
$166.57B | -23.3% | +5.7% | 26.8 | 1.3% |
|
SYK
Stryker Corp
|
$124.49B | -7.4% | +11.2% | 37.6 | 1.6% |
|
MDT
Medtronic plc
|
$106.32B | -12.8% | +8.4% | 22.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$66.29B | -53.2% | +5.5% | 18.7 | 2.0% |
|
EW
Edwards Lifesciences Corp
|
$54.80B | +11.6% | +11.5% | 50.6 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABT | +1.6% | +5.3% | -23.7% | +5.4% | -23.3% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -1.5% | +6.1% | -31.9% | +4.8% | -33.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.